Published in Cancer Chemother Pharmacol on April 18, 2007
Tubulin-interactive natural products as anticancer agents. J Nat Prod (2009) 1.59
Update on taxane development: new analogs and new formulations. Drug Des Devel Ther (2012) 1.36
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol (2010) 0.97
Designer lipids for drug delivery: from heads to tails. J Control Release (2014) 0.88
Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy. BMC Cancer (2012) 0.84
Nanoemulsion Formulation of a Novel Taxoid DHA-SBT-1214 Inhibits Prostate Cancer Stem Cell-Induced Tumor Growth. Cancer Lett (2017) 0.75
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 4.68
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2010) 1.81
Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 1.74
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther (2006) 1.66
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res (2009) 1.63
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res (2011) 1.61
MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 1.57
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother (2005) 1.50
LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology (2010) 1.47
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage (2005) 1.34
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol (2012) 1.33
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol (2010) 1.25
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res (2006) 1.24
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
Cancer vaccines and immunotherapy. Br Med Bull (2002) 1.07
Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng (2004) 1.04
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res (2009) 1.04
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother (2008) 1.03
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist (2006) 1.03
CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev (2014) 1.03
T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther (2010) 1.02
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol (2008) 1.02
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol (2005) 1.00
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol (2010) 0.99
Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Cancer Res (2013) 0.99
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol (2010) 0.99
Clinical trial design for target specific anticancer agents. Invest New Drugs (2003) 0.98
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother (2012) 0.98
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol (2005) 0.96
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol (2011) 0.95
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.95
Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother (2002) 0.95
Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene (2003) 0.94
Cholethorax following percutaneous transhepatic biliary drainage. Ulster Med J (2007) 0.94
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2005) 0.93
Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent. Hum Gene Ther (2010) 0.93
Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta (2004) 0.93
Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res (2007) 0.93
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid (2011) 0.93
Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther (2008) 0.92
Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer (2009) 0.92
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori (2011) 0.91
Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother (2009) 0.90
Cancer cell senescence: a new frontier in drug development. Drug Discov Today (2012) 0.90
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol (2006) 0.90
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother (2008) 0.89
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res (2005) 0.89
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs (2012) 0.89
Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol (2004) 0.89
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res (2004) 0.88
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res (2005) 0.88
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol (2005) 0.88
Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther (2005) 0.87
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer (2004) 0.87
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother (2011) 0.86
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res (2013) 0.86
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther (2008) 0.86
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother (2007) 0.85
Raising the profile of cancer of unknown primary. J Clin Oncol (2008) 0.85
Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis. Cytometry A (2010) 0.85
[Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis--retrospective study]. Ned Tijdschr Geneeskd (2010) 0.85
Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother (2014) 0.85
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother (2009) 0.85
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer (2010) 0.84
Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. J Gene Med (2010) 0.84
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods (2013) 0.84
Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum (2003) 0.84
Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding. Mol Ther (2010) 0.84
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 0.83
The epidermal growth factor receptor family in breast cancer. Onco Targets Ther (2008) 0.83
Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers. Dig Surg (2013) 0.83
CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer (2006) 0.83
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol (2002) 0.83
A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas (2006) 0.82
Telomerase-directed molecular therapeutics. Expert Rev Mol Med (2002) 0.82
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J Immunol (2014) 0.82
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat (2010) 0.82
Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist (2013) 0.81
Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev (2006) 0.81
[Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006]. Ned Tijdschr Geneeskd (2009) 0.81
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother (2011) 0.81
Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer (2010) 0.81
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother (2013) 0.80
5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.80
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology (2014) 0.80
Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncol (2008) 0.79